Sugi Predict

Sugi Predict / Compounds / Pyridine

Pyridine

Pyridine

SCHEMBL4528020

CC(N)=O.c1ccncc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 3/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ TSHR P16473 1/20 0.53
▸ LMNA P02545 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ PMP22 Q01453 1/20 0.47
▸ SIRT3 Q9NTG7 2/20 0.39
▸ F7 P08709 1/20 0.39
▸ F3 P13726 1/20 0.39
▸ SARM1 Q6SZW1 1/20 0.39
▸ SIRT2 Q8IXJ6 1/20 0.39
▸ SIRT6 Q8N6T7 1/20 0.39
▸ SIRT1 Q96EB6 1/20 0.39
▸ SIRT5 Q9NXA8 1/20 0.39
▸ SIRT4 Q9Y6E7 1/20 0.39
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL27295109 0.97 NAPRT (0.50) NAPRTTDP1TSHRLMNAALOX15
Pyridine SCHEMBL28212412 0.97 NAPRT (0.50) NAPRTTDP1TSHRLMNAALOX15
Pyridine SCHEMBL9134951 0.97 NAPRT (0.50) NAPRTTDP1TSHRLMNAALOX15
Pyridine SCHEMBL2007426 0.88 NAPRT (0.53) NAPRTTDP1TSHRLMNAALOX15
Pyridine SCHEMBL4881283 0.88 NAPRT (0.53) NAPRTTDP1TSHRLMNAALOX15
Pyridine SCHEMBL1070164 0.88 NAPRT (0.60) NAPRTTDP1TSHRLMNABLM
Pyridine SCHEMBL9065525 0.88 NAPRT (0.60) NAPRTTDP1TSHRSIRT3F7
Pyridine SCHEMBL179840 0.88 NAPRT (0.60) NAPRTTDP1TSHRLMNAKMT2A
Pyridine SCHEMBL10977701 0.88 NAPRT (0.60) NAPRTTDP1TSHRLMNAKMT2A
Pyridine SCHEMBL3467693 0.88 NAPRT (0.60) NAPRTTDP1TSHRLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107082884-A A kind of method for adsorbing purification dimethicone 王金桢 2017-08-22 — — CN claimed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 — — US claimed
CN-101343366-A Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof UNIV SHANGHAI (CN) 2009-01-14 — — CN claimed
CN-1311796-A Peptide antiangiogenic agents ABBOTT LAB (US) 2001-09-05 — — CN claimed
CN-117659023-A Pyridine acetamide derivative, pharmaceutical composition containing same and medical application of pyridine acetamide derivative 苏州阿尔脉生物科技有限公司 2024-03-08 — — CN disclosed
CN-117659023-A Pyridine acetamide derivative, pharmaceutical composition containing same and medical application of pyridine acetamide derivative 苏州阿尔脉生物科技有限公司 2024-03-08 — — CN disclosed
CN-109988124-B Inhibitor of renal glutaminase allosteric site containing oxygen group element diazole or tetrazole structure 杭州健昵福生物科技有限公司 2024-01-09 — — CN disclosed
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 — — US disclosed
CN-115340555-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-11-15 — — CN disclosed
CN-115340555-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-11-15 — — CN disclosed
CN-113173924-B Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-07-19 — — CN disclosed
CN-113173924-B Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-07-19 — — CN disclosed
WO-2005068444-A2 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-28 — — WO disclosed
CN-1118451-C Acylated derivatives of melatonin and its analogues, useful as medicaments CEMAF (FR) 2003-08-20 — — CN disclosed
CN-1311796-A Peptide antiangiogenic agents ABBOTT LAB (US) 2001-09-05 — — CN disclosed
CN-1196049-A Acylated derivatives of melatonin and its analogues, useful as medicaments CEMAF (FR) 1998-10-14 — — CN disclosed
CN-1037680-C Novel method of producing 7-(substituted)-9-[(substituted glycyl)-amido]-6-demethyl-6-deoxytetra-cyclines AMERICAN CYANAMID CO (US) 1998-03-11 — — CN disclosed
US-5449736-A Heat resistant and hydrophobic fluids as dielectrics RESEARCH FOUNDATION OF THE STATE OF NEW YORK (US) 1995-09-12 — — US disclosed
CN-86106980-A The alkylsulfonyl that 2-oxo-1-{[(replaces)-and amino] carbonyl } azetidine-typed — 1987-04-08 — — CN disclosed
EP-0181061-A1 Labelling organic molecules with sulphur-35 AMERSHAM INTERNATIONAL plc (GB) 1986-05-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof CDK9, CDK7, CDK8 NAPRT 1171/4885TDP1 3394/4885TSHR 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.